Diketopiperazine Microparticles with Defined Specific Surface Areas
AssigneeMannKind Corporation
InventorsMarshall L. Grant, Grayson W. Stowell, Paul Menkin, John J. Freeman, JR.
Life of this patent
Estimating the term…
Abstract
Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
Claims14
A dry powder comprising diketopiperazine microparticles having a specific surface area of 35 m2/g to about 67 m2/g.
A dry powder for inhalation comprising microparticles of a diketopiperazine of the formula:
- and a prostaglandin;
- wherein the microparticles have a specific surface area of 35 m2/g to about 67 m2/g.
A dry powder for inhalation comprising microparticles of a diketopiperazine of the formula:
- and granulocyte macrophage colony stimulating factor;
- wherein the microparticles have a specific surface area of 35 m2/g to about 67 m2/g.
A dry powder inhaler comprising a dry powder formulation comprising microparticles of a diketopiperazine having the formula:
- wherein the FDKP microparticles have a specific surface area of less than about 67 m2/g and one or more than one active agents.
Dependencies are inferred from the claim text.